These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38917523)

  • 1. The DNA methylation landscape across the TCR loci in patients with acute myeloid leukemia.
    Pospiech M; Beckford J; Kumar AMS; Tamizharasan M; Brito J; Liang G; Mangul S; Alachkar H
    Int Immunopharmacol; 2024 Sep; 138():112376. PubMed ID: 38917523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Digging deep into "dirty" drugs - modulation of the methylation machinery.
    Pleyer L; Greil R
    Drug Metab Rev; 2015 May; 47(2):252-79. PubMed ID: 25566693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA methylation landscape reveals LIN7A as a decitabine-responsive marker in patients with t(8;21) acute myeloid leukemia.
    He S; Li Y; Shi X; Wang L; Cai D; Zhou J; Yu L
    Clin Epigenetics; 2023 Mar; 15(1):37. PubMed ID: 36864492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response to Hypomethylating Agents in Myelodysplastic Syndrome Is Associated With Emergence of Novel TCR Clonotypes.
    Abbas HA; Reville PK; Jiang X; Yang H; Reuben A; Im JS; Little L; Sinson JC; Chen K; Futreal A; Garcia-Manero G
    Front Immunol; 2021; 12():659625. PubMed ID: 33912187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical update on hypomethylating agents.
    Duchmann M; Itzykson R
    Int J Hematol; 2019 Aug; 110(2):161-169. PubMed ID: 31020568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioinformatic analysis of the effects and mechanisms of decitabine and cytarabine on acute myeloid leukemia.
    Zhou S; Liu P; Zhang H
    Mol Med Rep; 2017 Jul; 16(1):281-287. PubMed ID: 28498449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials.
    Yun S; Vincelette ND; Abraham I; Robertson KD; Fernandez-Zapico ME; Patnaik MM
    Clin Epigenetics; 2016; 8():68. PubMed ID: 27307795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of genome-wide methylation and gene expression induced by 5-aza-2'-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia.
    Fabiani E; Leone G; Giachelia M; D'alo' F; Greco M; Criscuolo M; Guidi F; Rutella S; Hohaus S; Voso MT
    Leuk Lymphoma; 2010 Dec; 51(12):2275-84. PubMed ID: 21077739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypomethylating Agents as a Therapy for AML.
    Gardin C; Dombret H
    Curr Hematol Malig Rep; 2017 Feb; 12(1):1-10. PubMed ID: 28286907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decitabine-Mediated Epigenetic Reprograming Enhances Anti-leukemia Efficacy of CD123-Targeted Chimeric Antigen Receptor T-Cells.
    You L; Han Q; Zhu L; Zhu Y; Bao C; Yang C; Lei W; Qian W
    Front Immunol; 2020; 11():1787. PubMed ID: 32973749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Noncanonical immune response to the inhibition of DNA methylation by Staufen1 via stabilization of endogenous retrovirus RNAs.
    Ku Y; Park JH; Cho R; Lee Y; Park HM; Kim M; Hur K; Byun SY; Liu J; Lee YS; Shum D; Shin DY; Koh Y; Cho JY; Yoon SS; Hong J; Kim Y
    Proc Natl Acad Sci U S A; 2021 Mar; 118(13):. PubMed ID: 33762305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Features of the TCR repertoire associate with patients' clinical and molecular characteristics in acute myeloid leukemia.
    Pospiech M; Tamizharasan M; Wei YC; Kumar AMS; Lou M; Milstein J; Alachkar H
    Front Immunol; 2023; 14():1236514. PubMed ID: 37928542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decitabine induces very early in vivo DNA methylation changes in blasts from patients with acute myeloid leukemia.
    Claus R; Pfeifer D; Almstedt M; Zucknick M; Hackanson B; Plass C; Lübbert M
    Leuk Res; 2013 Feb; 37(2):190-6. PubMed ID: 23158571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA methylation landscape reveals GNAS as a decitabine-responsive marker in patients with acute myeloid leukemia.
    He S; Li Y; Wang L; Li Y; Xu L; Cai D; Zhou J; Yu L
    Neoplasia; 2024 Mar; 49():100965. PubMed ID: 38245923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML.
    Oellerich T; Schneider C; Thomas D; Knecht KM; Buzovetsky O; Kaderali L; Schliemann C; Bohnenberger H; Angenendt L; Hartmann W; Wardelmann E; Rothenburger T; Mohr S; Scheich S; Comoglio F; Wilke A; Ströbel P; Serve H; Michaelis M; Ferreirós N; Geisslinger G; Xiong Y; Keppler OT; Cinatl J
    Nat Commun; 2019 Aug; 10(1):3475. PubMed ID: 31375673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ascertaining QUAZARs: slow-motion and light-speed development of oral azacitidine and decitabine.
    Feld J; Tremblay D; Navada SC; Silverman LR
    Leuk Lymphoma; 2023 Mar; 64(3):525-539. PubMed ID: 36370098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different mechanisms of drug resistance to hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukemia.
    Šimoničová K; Janotka Ľ; Kavcová H; Sulová Z; Breier A; Messingerova L
    Drug Resist Updat; 2022 Mar; 61():100805. PubMed ID: 35227933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.
    Yang H; Bueso-Ramos C; DiNardo C; Estecio MR; Davanlou M; Geng QR; Fang Z; Nguyen M; Pierce S; Wei Y; Parmar S; Cortes J; Kantarjian H; Garcia-Manero G
    Leukemia; 2014 Jun; 28(6):1280-8. PubMed ID: 24270737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia.
    Yan P; Frankhouser D; Murphy M; Tam HH; Rodriguez B; Curfman J; Trimarchi M; Geyer S; Wu YZ; Whitman SP; Metzeler K; Walker A; Klisovic R; Jacob S; Grever MR; Byrd JC; Bloomfield CD; Garzon R; Blum W; Caligiuri MA; Bundschuh R; Marcucci G
    Blood; 2012 Sep; 120(12):2466-74. PubMed ID: 22786882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Azacitidine improves the T-cell repertoire in patients with myelodysplastic syndromes and acute myeloid leukemia with multilineage dysplasia.
    Fozza C; Corda G; Barraqueddu F; Virdis P; Contini S; Galleu A; Isoni A; Dore F; Angelucci E; Longinotti M
    Leuk Res; 2015 Sep; 39(9):957-63. PubMed ID: 26209197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.